Study S003243

A Randomized, Double-blind, Placebo-controlled, Multicenter, Multiple Ascending Dose Phase Ib Study in Subjects With Type 2 Diabetes to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TG103 Injection

ClinicalTrials.gov record

Registration

Registration: NCT04790006
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: UNKNOWN
Enrollment: 54
Start: 2021-04
Primary completion: 2022-03
Lead sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions: Type 2 Diabetes
Interventions: DRUG:TG103; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Safety and tolerability assessed by incidence and severity of adverse events [up to 15 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.